MAPT and Alzheimer disease: Upon closer analysis, when the expression level of tau, that is yet to aggregate, was reduced later in the lifespan of these mice, some of the initially observed AD pathology-related phenotypes were ameliorated despite the prevalence of tau aggregates (Santacruz et al., 2005).